CD86 Recombinant Rabbit Monoclonal Antibody [44E09]
CD28LG2; T-lymphocyte activation antigen CD86; Activation B7-2 antigen; B70; BU63; CTLA-4 counter-receptor B7.2; FUN-1; CD antigen CD86; B7-2; B7.2; LAB72; CD86
01产品图片
![点击查看大图 CD86 Recombinant Rabbit Monoclonal Antibody [44E09]](../../assets/uploads/76c70ff1d916-mvvnjtkc.webp)
02产品简介
CD28LG2; T-lymphocyte activation antigen CD86; Activation B7-2 antigen; B70; BU63; CTLA-4 counter-receptor B7.2; FUN-1; CD antigen CD86; B7-2; B7.2; LAB72; CD86
03产品介绍
CD28LG2; T-lymphocyte activation antigen CD86; Activation B7-2 antigen; B70; BU63; CTLA-4 counter-receptor B7.2; FUN-1; CD antigen CD86; B7-2; B7.2; LAB72; CD86
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Affinity-chromatography
Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20°C storage.
WB 1:1000-1:5000 IF-C 1:100-1:800 IP 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate.
Immunogen Information
942 (Human) 12524 (Mouse) 56822 (Rat)
认真做好每一个抗体, 每一个抗体都经过反复验证!
Preventing post-surgical recurrence and metastasis in advanced gastric cancer through tumor vaccines necessitates a more surgically compatible strategy. Here, we propose an intraoperatively applicable platform featuring a self-adjuvant tumor vaccine co-delivered with PD-1 blockade in fibrin gel (FG) to inhibit post-surgical tumor relapse. First, the tumor cell membrane vaccine is modified via simple insertion of DSPE-PEG-αCD40, which simultaneously endows the vaccine with targeting and self-adjuvant effects on antigen-presenting cells (APCs). This αCD40-modified vaccine (Vax-αCD40) significantly stimulates dendritic cell maturation and reprograms macrophages toward pro-inflammatory phenotypes in vitro and in vivo. Moreover, when Vax-αCD40 and αPD-1 are encapsulated within FG to form an adhesive “vaccine pool”, a positive feedback loop of CD40 expression-αCD40 stimulation on APCs exerts synergistic immune activation at the surgical site. In mouse models, this co-delivery system effectively suppresses local recurrence and peritoneal metastasis, which is associated with increased APC infiltration, cytotoxic CD8 + T cell expansion, and durable immune memory. This strategy represents a translatable approach for preventing recurrence in gastrointestinal malignancies.
Authors:Jianming Yang, Chi Chen, Dongbing Ding, Jiannan Ren, Tianyun Lan, Yiquan Li, Guangchun Jiang, Rongpu Liang, Jiarong You, Bekhzod Abdullaev, Svetlana Ryabtseva, He Huang, Xintao Shuai, Bo Wei
Acute lung injury (ALI) is a life-threatening inflammatory syndrome closely associated with reactive oxygen species (ROS) burst and dysregulation of M1/M2 macrophage polarization. Therefore, immune regulation of pulmonary macrophages represents a potential strategy to alleviate lung damage. However, existing approaches suffer from imprecise cellular targeting, monofunctional therapeutic effects, and suboptimal biocompatibility. To address these issues, an inhalable, multifunctional biomimetic nanoplatform is proposed that mimics apoptotic bodies (CTM@PS-Lip). CTM@PS-Lip is synthesized by fabricating nanoscale liposomes based on the outer leaflet structure of apoptotic cell membranes and encapsulating ROS responsive carbon dots (CDs)-methylprednisolone (MP) conjugates. Upon inhalation, liposomes rich in phosphatidylserine (PS) can transmit the “eat me” signal, efficiently inducing macrophages to recognize and phagocytose. Subsequently, the high ROS microenvironment in ALI-affected lung tissues triggers the controlled cargo release for: not only promoting the MP-mediated immunomodulatory effects by inhibiting M1 macrophage polarization and inducing M2 macrophage polarization but also synergizing with the potent CDs mediated ROS-scavenging capacity, significantly reducing pulmonary inflammation and promoting tissue repair. Thus, CTM@PS-Lip integrates imaging, therapy, and biosafety, proving to be a promising strategy for safe and efficient management in ALI.
Glaucoma is a leading cause of irreversible blindness, characterized by the progressive degeneration of retinal ganglion cells (RGCs) and optic nerve damage. Although current intraocular pressure (IOP)-lowering therapies exhibit varying degrees of efficacy in preventing RGC loss, neurodegeneration can persist even in cases where IOP remains within the normal range, underscoring the need for direct neuroprotective strategies. Emerging evidence suggests that neuroinflammation mediated by retinal microglia plays a pivotal role in the pathogenesis of glaucoma. Here, a nucleic acid-based nanotherapeutic platform is proposed that employs tetrahedral framework nucleic acids (tFNAs) conjugated with microRNA-124 (miR-124), referred to as Tmi, to achieve targeted immunomodulation. Compared with conventional delivery systems, this self-assembled nanostructure exhibits superior cellular penetration and nucleic acid protection capabilities. Mechanistic studies demonstrate that Tmi-mediated inhibition of the STAT3 pathway attenuates excessive microglial activation, reduces migration-associated inflammation, and suppresses pathological cell migration in an acute ocular hypertension model. This is an alternative treatment strategy beyond intraocular pressure control, offering greater possibilities for exploring therapies for acute high intraocular pressure glaucoma.
International Journal of Nanomedicine IF:8.7 Authors:Zhouyu Yang, Ke Li, Xinru Li, Pei Zhong, Yuqian Hu, Xin Yao Authors:Ma Ya-nan, Wang Zijie, Liang Yuchang, Tan Guoao, Hu Xiqi, Xia Ying Authors:Ziran He, Zhenhua Zhang, Li Ding, Shan Long, Liu Yang, Ce Hu, MengXue Long, Zhiqiang Liu
Background Lung cancer exhibits high mortality and incidence rates, with tumor-associated macrophages (TAMs) serving as critical contributors to cancer progression. This study investigates the unexplored mechanistic role of HRD1—an E3 ubiquitin ligase implicated in cancer — in orchestrating TAM polarization to affect lung cancer pathogenesis. Methods HRD1 expression in lung cancer using TCGA database and validated its impact via IHC. THP-1 cells and macrophages isolated from murine tumor tissues via magnetic bead sorting were transfected with the oe-HRD1 plasmid, followed by flow cytometry, ELISA, and RT-qPCR assays to investigate HRD1's regulatory effects on macrophage polarization and function. Co-IP was employed to investigate interactions between USP7 and HRD1/PD-L1, while Immunofluorescence elucidated underlying mechanisms. Results HRD1 was highly expressed in lung cancer and promotes tumor growth in tumor-bearing mice and proliferation in THP-1 cells. Strikingly, both in vivo and in vitro overexpression of HRD1 drove macrophage M2 polarization. Mechanistically, USP7 interacted independently with HRD1 and PD-L1, while HRD1 binding to USP7 facilitated PD-L1 ubiquitination. Furthermore, HRD1 overexpression upregulated USP7 expression, thereby enhancing M2 polarization. Conclusion HRD1 promotes lung cancer progression by regulating TAM M2 polarization via USP7, offering novel therapeutic targets and diagnostic perspectives for early-stage lung cancer intervention.
Authors:Yezhou Xia, Xiaowu Tan, Saili Zeng, Yixia Jiang JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS IF:3.8 Authors:Xueqin Sun, Dongbo Cao, Wuping Li, Kai Jiang, Fuping Zhu, Dan Luo Authors:Chanjuan Chen, Jingwen Hao, Yuan Liu, Qi Wan
相关资料下载:说明书(点击从官网下载)
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2016 年
- 所在地
- 湖南
- 收录条目
- 498 个
- 平台核验
- 平台代管
06品牌与供应商
公司产品涵盖抗体、细胞、培养基、质粒载体等多个领域,致力于为生命科学研究提供可靠的工具与解决方案。自创立以来,艾碧维始终秉持“求实、诚挚、勤勉、克己”的发展理念,坚持以自主研发与持续创新为核心动力。公司拥有百余人的团队,其中硕士及以上学历生物医学专业人才占比超过30%,包括博士4人,构建起一支结构合理、专业扎实的研发与服务队伍。通过设立研发部、生产部、市场与营销部、财务部等多功能部门,公司实现了从产品开发到市场推广的全流程管控。艾碧维不仅敢于质疑现状,积极为生命科学家突破技术壁垒提供支撑,更注重与客户的深度互动与合作,通过持续收集反馈、开展研发协作,提前预见并解决潜在问题。未来,公司将继续秉持“助力科研创新,让实验更简单”的使命,一步一个脚印地打造具有国际领先水平的技术研发与产业化平台,为全球生命科学领域的进步持续赋能。注意: 1.本公司产品仅供科研使用。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
艾碧维 在本目录共 498 个条目,除本条外还有:
科研在线(TeleVM). CD86 Recombinant Rabbit Monoclonal Antibody [44E09](AWA12696)[EB/OL]. 产品目录, 2026-10-31. https://www.suprotek.cn/products/item/cd86-recombinant-rabbit-monoclonal-antibody-44e09.html.
TeleVM. (2026, October 31). CD86 Recombinant Rabbit Monoclonal Antibody [44E09](AWA12696). 产品目录. https://www.suprotek.cn/products/item/cd86-recombinant-rabbit-monoclonal-antibody-44e09.html
@misc{biocsp_item_cd86_recombinant_rabbit_monoclonal_antibody_44e09,
title = {CD86 Recombinant Rabbit Monoclonal Antibody [44E09](AWA12696)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-10-31,产品目录},
url = {https://www.suprotek.cn/products/item/cd86-recombinant-rabbit-monoclonal-antibody-44e09.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源